

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

3665-167

10/560,774

APPLICANT

SCHWEIGHOFFER et al.

(Use several sheets if necessary)

FILING DATE

GROUP

December 14, 2005

1627

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2010/0204251 A1	08/2010	Ait Ikhlef et al.			
	6,855,736	02/2005	Ait Ikhlef et al.			
	2004/0219552 A1	11/2004	Ait Ikhlef et al.			
	5,919,801	07/1999	Dhainaut et al.			

FOREIGN PATENT DOCUMENTS

DOCUMENT			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Office Action dated April 5, 2011, issued in connection with U.S. Application No. 12/628,561
	Arvin et al, "The Role of Inflammation and Cytokines in Brain Injury", Neuroscience and Biobehavioral Reviews. 20(3); 1996:445-452
	Cavalla et al, "Phosphodiesterase IV Inhibitors: Structural Diversity and Therapeutic Potential in Asthma", Current Medicinal Chemistry. 1995; 2:561-572
	Rothstein, "Therapeutic Horizons for Amyotrophic Lateral Sclerosis", Curr Opin Neurobiol. 1996; Oct; 6(5):679-687
	Koh, "Activation of the metabotropic glutamate receptor attenuates N-methyl-D-aspartate neurotoxicity in cortical cultures" PNAS 1991 (88) 9431-9435
	Sattler, "Molecular Mechanisms of Glutamate Receptor-Mediated Excitotoxic Neuronal Cell Death" Molecular Neurobiology (2001) 24, 107-129
	Morciano, "Guanine nucleotides inhibit NMDA and kainate-induced neurotoxicity in cultured rat hippocampal and neocortical neurons" Neurochemistry International 45 (2004) 95-101
	Frandsen, "Direct Evidence That Excitotoxicity in Cultured Neurons Is Mediated via N-Methyl-D-Aspartate (NMDA) as well as Non-NMDA Receptors" J. Neurochem (1989) 53 (1) 297-299
	Frandsen, "Novel Glutamate Receptor Antagonists Selectively Protect Against Kainic Acid Neurotoxicity in Cultured Cerebral Cortex Neurons" J. Neurochem (1990) 55 (5) 1821-1823
	ExonHit Therapeutics, Press Release, "ExonHit announces last patient out of EHT 0202 Phase IIa study in Alzheimer" (June 16, 2009)

*Examiner		Date Considered	
-----------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.